<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834379</url>
  </required_header>
  <id_info>
    <org_study_id>B006511</org_study_id>
    <nct_id>NCT00834379</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative bioavailability of pravastatin sodium&#xD;
      40 mg tablets with that of Pravachol® 40 mg tablets in healthy adult male subjects under&#xD;
      fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">September 2000</completion_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pravastatin 40 mg Tablet (test) dosed in first period followed by Pravachol® 40 mg Tablet (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravachol®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pravachol® 40 mg Tablet (reference) dosed in first period followed by Pravastatin 40 mg Tablet (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pravastatin sodium</intervention_name>
    <description>40 mg Tablet</description>
    <arm_group_label>Pravastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravachol®</intervention_name>
    <description>40 mg tablet</description>
    <arm_group_label>Pravachol®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Non-institutionalized subjects consisting of university students and members of the&#xD;
             community at large.&#xD;
&#xD;
          -  All subjects selected for this study will be males 18 to 45 (inclusive) years of age.&#xD;
             Weight of the subjects shall not be more than 15% ± from the normal for height and&#xD;
             body frame (Metropolitan Life, 1993, Height, Weight, Body Chart).&#xD;
&#xD;
          -  Each subject shall be given a general physical examination within 21 days of&#xD;
             initiation of the study. Such examination includes, but is not limited to, blood&#xD;
             pressure, general observations, and history.&#xD;
&#xD;
        At the end of the study the subjects will have an exit evaluation consisting of interim&#xD;
        history, global evaluation, and clinical laboratory measurements.&#xD;
&#xD;
        Adequate blood and urine samples should be obtained within 21 days before the beginning of&#xD;
        the first period and at the end of the trial for clinical laboratory measurements.&#xD;
&#xD;
        Clinical laboratory measurements will include the following:&#xD;
&#xD;
        Hematology: hemoglobin, hematocrit, red blood cell count, platelets, and white blood cell&#xD;
        count (with differential)&#xD;
&#xD;
        Clinical Chemistry: creatinine, BUN, glucose, SGOT, SGPT, bilirubin, and alkaline&#xD;
        phosphatase&#xD;
&#xD;
        Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood,&#xD;
        and cells&#xD;
&#xD;
        HIV Screen: (pre-study only)&#xD;
&#xD;
        Hepatitis-B, C Screen: (pre-study only)&#xD;
&#xD;
        Drugs of Abuse Screen: (pre-study and at each dosing period check-in)&#xD;
&#xD;
        Subjects will be selected if all above are normal. Electrocardiograms of all participating&#xD;
        subjects will be recorded before initiation of the study and filed with each subject's case&#xD;
        report forms.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Subjects with a history of chronic alcohol consumption, drug addiction, or serious&#xD;
             gastrointestinal, renal, hepatic, or cardiovascular disease, tuberculosis, epilepsy,&#xD;
             asthma, diabetes, psychosis or glaucoma will not be eligible for this study.&#xD;
&#xD;
          -  Subjects whose clinical laboratory test values are greater than 20% outside the normal&#xD;
             range may be retested. If the clinical values are outside the range on retesting the&#xD;
             subject will not be eligible to participate in the study unless the clinical&#xD;
             investigator deems the result to not be significant.&#xD;
&#xD;
          -  Subjects who have a history of allergic responses to the class of drug being tested&#xD;
             should be excluded from the study.&#xD;
&#xD;
          -  Subjects who use tobacco in any form will not be eligible to participate in the study.&#xD;
             Three months abstinence is required.&#xD;
&#xD;
          -  All subjects will have urine samples assayed for the presence of drugs of abuse as&#xD;
             part of the clinical laboratory screening procedures and at each dosing period&#xD;
             check-in. Subjects found to have urine concentrations of any of the tested drugs will&#xD;
             not be allowed to participate.&#xD;
&#xD;
          -  Subjects should not have donated blood and/or plasma for at least thirty (30) days&#xD;
             prior to the first dosing of the study.&#xD;
&#xD;
          -  Subjects who have taken any investigational drug within thirty (30) days prior to the&#xD;
             first dosing of the study will not be allowed to participate.&#xD;
&#xD;
          -  Subjects who have been exposed to known hepatic enzyme inducing or inhibiting agents&#xD;
             within (30) days prior to dosing will not be allowed to participate.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Yeung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharma Medica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharma Medica Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1R 5A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

